Filing Details

Accession Number:
0001415889-21-006265
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-28 17:41:13
Reporting Period:
2021-12-23
Accepted Time:
2021-12-28 17:41:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1800 Abbott Laboratories ABT Pharmaceutical Preparations (2834) 360698440
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1778070 F Andrea Wainer 100 Abbott Park Road
Abbott Park IL 60064
Executive Vice President No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Without Par Value Acquisiton 2021-12-23 3,000 $47.00 52,782 No 4 M Direct
Common Shares Without Par Value Acquisiton 2021-12-23 10,000 $38.40 62,782 No 4 M Direct
Common Shares Without Par Value Disposition 2021-12-23 13,000 $140.00 49,782 No 4 S Direct
Common Shares Without Par Value Acquisiton 2021-12-27 3,000 $47.00 52,782 No 4 M Direct
Common Shares Without Par Value Disposition 2021-12-27 3,000 $142.50 49,782 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Option (right to buy) Disposition 2021-12-23 3,000 $0.00 3,000 $47.00
Common Shares Option (right to buy) Disposition 2021-12-23 10,000 $0.00 10,000 $38.40
Common Shares Option (right to buy) Disposition 2021-12-27 3,000 $0.00 3,000 $47.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,226 2018-02-20 2025-02-19 No 4 M Direct
5,000 2019-02-19 2026-02-18 No 4 M Direct
8,226 2018-02-20 2025-02-19 No 4 M Direct
Footnotes
  1. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.